DIRECT Therapies SIGNED
Diabetes Immunoengineering: Redesigning Encapsulated Cell Transplant Therapies
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0DIRECT Therapies project word cloud
Explore the words cloud of the DIRECT Therapies project. It provides you a very rough idea of what is the project "DIRECT Therapies" about.
Project "DIRECT Therapies" data sheet
The following table provides information about the project.
| Coordinator |
THE UNIVERSITY OF NOTTINGHAM
Organization address contact info |
| Coordinator Country | United Kingdom [UK] |
| Total cost | 269˙857 € |
| EC max contribution | 269˙857 € (100%) |
| Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
| Code Call | H2020-MSCA-IF-2017 |
| Funding Scheme | MSCA-IF-GF |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-05-01 to 2021-04-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | THE UNIVERSITY OF NOTTINGHAM | UK (NOTTINGHAM) | coordinator | 269˙857.00 |
| 2 | CHILDREN'S HOSPITAL CORPORATION | US (BOSTON) | partner | 0.00 |
Map
Project objective
Diabetes Immunoengineering: Redesigning Encapsulated Cell Transplant Therapies Diabetes remains a global healthcare challenge, affecting 370 million people worldwide. Islet transplantation offers the potential to restore insulin function in diabetes-1 patients, and is proving successful in human clinical trials. However a major limitation is the requirement for patients to take global immunosuppressive drugs, often daily, for the remainder of their lives. These drugs can impact the quality of life for the patient, and may lead to an impaired immune system at risk of opportunistic pathogens. The scientific aim of this project is to develop innovative multifunctional materials for diabetes-1 cell therapies; those that can better support islet function and also direct the host immune system, removing the need for global immune suppression and enhancing transplant lifetimes. This project connects a talented young researcher with a background in chemistry, biomaterials science and immunoengineering, to a host institution with expertise in drug delivery and tissue engineering (Nottingham), and an internationally renowned outgoing institution (Boston Children's Hospital, Harvard Medical School) with expertise in transplant encapsulation and diabetes therapies. Combining the localised drug delivery expertise of the host institution, the diabetes-1 cell therapy transplant knowledge of the outgoing institution, and the researcher’s own expertise in immunoengineering presents a unique opportunity and new approach to addressing this healthcare challenge, and facilitates development of the researcher's career through a specified training-in-research program. Bridging the gap between the transplant immunology, biomaterials and drug delivery fields in this way meets the “Open Innovation, Open Science, Open to the World” EU vision towards Open Science and follows the road map for integrative research proposed by the UK Medical Research Councils for regenerative medicine research.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DIRECT THERAPIES" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "DIRECT THERAPIES" are provided by the European Opendata Portal: CORDIS opendata.